|
|
|||||||
Letter |
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening Epstein-Barr virus (EBV)-driven B-cell malignancy occurring in 1 to 3% of renal transplant patients. Recently, EBV DNA quantification has become a useful tool for identifying patients at risk of developing PTLD. However, studies on EBV load differ in design, methodology and type of patients.
This article has been cited by other articles:
![]() |
H. Williams and D. H. Crawford Epstein-Barr virus: the impact of scientific advances on clinical practice Blood, February 1, 2006; 107(3): 862 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Kotton and J. A. Fishman Viral Infection in the Renal Transplant Recipient J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1758 - 1774. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |